BidaskClub upgraded shares of Quest Diagnostics Incorporated (NYSE:DGX) from a sell rating to a hold rating in a research note released on Tuesday.

Several other brokerages have also recently issued reports on DGX. Deutsche Bank AG restated a buy rating and issued a $115.00 price objective (up from $108.00) on shares of Quest Diagnostics in a research note on Sunday, April 23rd. Bank of America Corporation upgraded Quest Diagnostics from a neutral rating to a buy rating and raised their price objective for the stock from $111.00 to $118.00 in a research note on Tuesday, July 25th. Zacks Investment Research cut Quest Diagnostics from a buy rating to a hold rating in a research note on Monday, May 22nd. Raymond James Financial, Inc. upgraded Quest Diagnostics from a market perform rating to an outperform rating and set a $116.00 price objective for the company in a research note on Friday, April 21st. Finally, Evercore ISI restated an in-line rating and issued a $104.50 price objective (up from $102.00) on shares of Quest Diagnostics in a research note on Monday, April 24th. One analyst has rated the stock with a sell rating, nine have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $109.62.

Quest Diagnostics (NYSE DGX) opened at 104.87 on Tuesday. The company has a market cap of $14.30 billion, a PE ratio of 21.13 and a beta of 0.69. Quest Diagnostics has a 52 week low of $79.12 and a 52 week high of $112.96. The company has a 50-day moving average of $108.23 and a 200-day moving average of $103.54.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.13. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The firm had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. During the same period last year, the business posted $1.34 earnings per share. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, equities analysts expect that Quest Diagnostics will post $5.69 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Quest Diagnostics Incorporated (DGX) Upgraded to “Hold” at BidaskClub” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/19/quest-diagnostics-incorporated-dgx-upgraded-to-hold-at-bidaskclub.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 18th. Stockholders of record on Tuesday, October 3rd will be given a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.72%. The ex-dividend date is Monday, October 2nd. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.29%.

In other news, SVP Catherine T. Doherty sold 59,762 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $107.55, for a total value of $6,427,403.10. Following the completion of the sale, the senior vice president now directly owns 78,582 shares in the company, valued at $8,451,494.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey M. Leiden sold 296 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $106.66, for a total value of $31,571.36. Following the completion of the sale, the director now owns 6,000 shares of the company’s stock, valued at $639,960. The disclosure for this sale can be found here. Insiders sold 61,362 shares of company stock valued at $6,600,758 over the last 90 days. Company insiders own 1.50% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. WFG Advisors LP boosted its stake in Quest Diagnostics by 45.3% in the second quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock worth $107,000 after buying an additional 301 shares during the period. Sun Life Financial INC boosted its stake in Quest Diagnostics by 14,142.9% in the second quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock worth $111,000 after buying an additional 990 shares during the period. YorkBridge Wealth Partners LLC boosted its stake in Quest Diagnostics by 1.5% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,188 shares of the medical research company’s stock worth $127,000 after buying an additional 18 shares during the period. Parallel Advisors LLC boosted its stake in Quest Diagnostics by 16.1% in the first quarter. Parallel Advisors LLC now owns 1,279 shares of the medical research company’s stock worth $137,000 after buying an additional 177 shares during the period. Finally, Advisors Capital Management LLC acquired a new stake in Quest Diagnostics during the first quarter worth approximately $164,000. Institutional investors and hedge funds own 90.06% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Stock Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related stocks with our FREE daily email newsletter.